

Ruxolitinib cream results in greater repigmentation in vitiligo

October 20 2022



For patients with vitiligo, ruxolitinib cream results in greater

repigmentation of lesions compared with vehicle control, according to a study published online Oct. 20 in the *New England Journal of Medicine*.

David Rosmarin, M.D., from Tufts Medical Center in Boston, and colleagues conducted two phase 3 trials involving [patients](#) aged 12 years or older with nonsegmental [vitiligo](#) with depigmentation covering 10 percent or less of total body surface area. Patients were randomly assigned to apply 1.5 percent ruxolitinib cream or vehicle control twice daily for 24 weeks in a 2:1 ratio, after which all patients could apply ruxolitinib cream through week 52. A total of 674 patients were enrolled: 330 in the Topical Ruxolitinib Evaluation in Vitiligo Study 1 (TruE-V1) and 344 in TRuE-V2.

The researchers found that the percentage of patients with a decrease of at least 75 percent from baseline in the facial Vitiligo Area Scoring Index response at week 24 was 29.8 percent in the ruxolitinib group and 7.4 percent in the vehicle group (relative risk [RR], 4.0) in TRuE-V1. The corresponding percentages were 30.9 percent and 11.4 percent, respectively, in TRuE-V2 (RR, 2.7). The superiority of ruxolitinib over vehicle control was demonstrated in key secondary end points. Adverse events occurred in 54.8 percent of patients in TRuE-V1 and 62.3 percent of patients in TRuE-V2 who applied ruxolitinib cream through 52 weeks.

"Ruxolitinib cream showed superiority to vehicle control in repigmentation of vitiligo. Patient-reported outcomes suggest that changes were meaningful to patients, although there were no substantial between-group differences in quality of life," the authors write.

More information: David Rosmarin et al, Two Phase 3, Randomized, Controlled Trials of Ruxolitinib Cream for Vitiligo, *New England Journal of Medicine* (2022). [DOI: 10.1056/NEJMoa2118828](https://doi.org/10.1056/NEJMoa2118828)

2022 HealthDay. All rights reserved.

Citation: Ruxolitinib cream results in greater repigmentation in vitiligo (2022, October 20)
retrieved 4 June 2024 from

<https://medicalxpress.com/news/2022-10-ruxolitinib-cream-results-greater-repigmentation.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.